[1]王怡璇,曹永亮,高萌,等.视网膜深层血流密度对康柏西普治疗糖尿病性黄斑水肿预后的影响：基于OCTA的评价[J].眼科新进展,2022,42(4):299-303.[doi:10.13389/j.cnki.rao.2022.0060]
　WANG Yixuan,CAO Yongliang,GAO Meng,et al.Effect of vessel density in retinal deep capillary plexus on the prognosis of diabetic macular edema treated with Conbercept based on optical coherence tomography angiography[J].Recent Advances in Ophthalmology,2022,42(4):299-303.[doi:10.13389/j.cnki.rao.2022.0060]
点击复制

视网膜深层血流密度对康柏西普治疗糖尿病性黄斑水肿预后的影响：基于OCTA的评价/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年4期
页码:
299-303
栏目:
应用研究
出版日期:
2022-04-05

文章信息/Info

Title:
Effect of vessel density in retinal deep capillary plexus on the prognosis of diabetic macular edema treated with Conbercept based on optical coherence tomography angiography
作者:
王怡璇; 曹永亮; 高萌; 孙艳; 王淑娜
261000　山东省潍坊市，潍坊医学院附属医院眼科中心
Author(s):
WANG Yixuan; CAO Yongliang; GAO Meng; SUN Yan; WANG Shuna
Department of Ophthalmology,the Affiliated Hospital of Weifang Medical University,Weifang 261000,Shandong Province,China
关键词:
视网膜深层毛细血管丛; 糖尿病性黄斑水肿; 血管内皮生长因子; OCTA
Keywords:
retinal deep capillary plexus;  diabetic macular edema;  vascular endothelial growth factor;  optical coherence tomography angiography
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2022.0060
文献标志码:
A
摘要:
目的　研究糖尿病性黄斑水肿（DME）患者视网膜深层毛细血管丛（DCP）的血流密度（VD）与康柏西普治疗预后的关系。方法　回顾性分析2020年1月至2021年7月就诊于潍坊医学院附属医院眼科中心的46例非增生型糖尿病视网膜病变（NPDR)期DME患者（DME组）和同期37例无DME的NPDR患者（对照组）资料。DME组患者连续3次玻璃体内注射康柏西普，根据3次治疗后黄斑中心视网膜厚度(CRT)的降低程度分为有效组（>50 μm）和疗效欠佳组（≤50 μm）。OCTA测量患者治疗前及治疗后1个月、3个月的视网膜浅层毛细血管丛VD（SCP-VD）、DCP-VD、CRT、黄斑中心凹无血管区（FAZ）面积、FAZ旁300 μm的血流密度(FD300)等参数，分析各参数的差异及相关性。结果　DME组患者整体、中心凹和旁中心凹SCP-VD、DCP-VD均较对照组低，差异均有统计学意义（均为P<0.05）；除CRT外，DME组患者治疗后1个月、3个月的OCTA参数与治疗前比较差异均无统计学意义（均为P>0.05）；DME组患者治疗后1个月、3个月BCVA（logMAR)（0.38±0.28、0.37±0.29）均较治疗前（0.54±0.39）显著提高，治疗后1个月CRT［（327.457±73.684）μm］、治疗后3个月CRT［（304.761±58.537）μm］均较治疗前［（380.065±82.685)μm］显著降低（均为P<0.05）；有效组患者中心凹DCP-VD（36.258%±13.187%） 较疗效欠佳组（28.564%±8.855%）大（P=0.024），两组患者间其余OCTA参数（FAZ面积、FD300、整体SCP-VD、中心凹SCP-VD、旁中心凹SCP-VD、整体DCP-VD、旁中心凹DCP-VD、CRT）差异均无统计学意义（均为P>0.05）；DME组患者治疗前中心凹DCP-VD与治疗后3个月CRT下降值呈正相关（P=0.040），患者治疗前整体DCP-VD和旁中心凹DCP-VD与治疗后3个月BCVA提高值均呈正相关（P=0.033、0.036），余参数间均无明显相关性（均为P>0.05）。结论　DME患者DCP-VD与黄斑水肿的发展密切相关， DCP-VD可能可以作为预测DME患者抗VEGF治疗预后的指标。
Abstract:
Objective　To investigate the correlation between the vessel density (VD) in retinal deep capillary plexus (DCP) and the prognosis of patients with diabetic macular edema (DME) treated with Conbercept. Methods　This was a retrospective study. A total of 46 DME patients with non-proliferative diabetic retinopathy (NPDR) were selected into the DME group, and 37 NPDR patients without DME were selected into the control group. Patients in the DME group were subdivided into the effective group (>50 μm) and ineffective group (≤50 μm) according to the reduction of central retinal thickness (CRT) after three consecutive intravitreal injections of Conbercept. The vessel density in superficial capillary plexus (SCP-VD), vessel density in deep capillary plexus (DCP-VD), CRT, foveal avascular zone (FAZ), VD in a 300-μm-wide region around the FAZ (FD300) and other parameters were measured by optical coherence tomography angiography (OCTA) before, 1 month and 3 months after treatment with Conbercept, and their correlations were analyzed.Results　Compared with the control group, the global, foveal and parafoveal SCP-VD and DCP-VD in the DME group were significantly lower (all P<0.05). Except CRT, OCTA parameters in the DME group at 1 month and 3 months after treatment had no significant difference compared with those before treatment (all P>0.05). The BCVA (logMAR) in the DME group was 0.38±0.28 at 1 month after treatment and 0.37±0.29 at 3 months after treatment, significantly better than that before treatment (0.54±0.39) (both P<0.05). The CRT in the DME group was (327.457±73.684)μm at 1 month after treatment and (304.761±58.537)μm at 3 months after treatment, significantly lower than that before treatment ［(380.065±82.685)μm］ (both P<0.05). The foveal DCP-VD in the effective group ［(36.258±13.187) %］ was higher than that in the ineffective group ［(28.564±8.855) %］ (P=0.024), while other OCTA parameters (FAZ, FD300, global SCP-VD, foveal and parafoveal SCP-VD, global and parafoveal DCP-VD, CRT) had no significant difference between the two groups (all P>0.05). The preoperative foveal DCP-VD was positively correlated with the CRT decrease at 3 months after treatment (P=0.040). The global and parafoveal DCP-VD at baseline were positively correlated with the BCVA recovery at 3 months after treatment (P=0.033, 0.036). There was no correlation between the rest parameters (all P>0.05).Conclusion　DCP-VD is closely related to the development of macular edema in DME patients. It may be used as an indicator to predict the prognosis of anti-vascular endothelial growth factor therapy in DME patients.

参考文献/References:

［1］　PODKOWINSKI D,BEKA S,MURSCH-EDLMAYR A S,STRAUSS R W,FISCHER L,BOLZ M.A swept source optical coherence tomography angiography study:imaging artifacts and comparison of non-perfusion areas with fluorescein angiography in diabetic macular edema［J］.PLoS One,2021,16(4):e0249918.
［2］　PARK Y G,PARK Y H.Quantitative analysis of retinal microvascular perfusion and novel biomarkers of the treatment response in diabetic macular cdema［J］.Diabetes Res,2020,2020:2132037.
［3］　ELNAHRY A G,ABDEL-KADER A A,RAAFAT K A,ELRAKHAWY K.Evaluation of changes in macular perfusion detected by optical coherence tomography angiography following 3 intravitreal monthly bevacizumab injections for diabetic macular edema in the IMPACT Study［J］. Ophthalmology,2020,2020:5814165.
［4］　BA T,ZHOU L,ZHANG H,ZHANG X,GUO S,LI H,et al.Evaluation of the efficacy of Conbercept in the treatment of diabetic macular edema based on OCTA［J］.Medicine (Baltimore),2020,99(35):e21992.
［5］　BUSCH C,WAKABAYASHI T,SATO T,FUKUSHIMA Y,HARA C,SHIRAKI N,et al.Retinal microvasculature and visual acuity after intravitreal aflibercept in diabetic macular edema:an optical coherence tomography angiography Study［J］.Sci Rep,2019,9(1):1561.
［6］　BABIUCH A S,CONTI T F,CONTI F F,SILVA F Q,RACHITSKAYA A,YUAN A,et al.Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study):6-month interim analysis［J］.Int J Retina Vitreous,2019,5:17.
［7］　HIRANO T,KITAHARA J,TORIYAMA Y,KASAMATSU H,MURATA T,SADDA S.Quantifying vascular density and morphology using different swept-source optical coherence tomography angiographic scan patterns in diabetic retinopathy［J］.Br J Ophthalmol,2019,103(2):216-221.
［8］　BROWNING D J,STEWART M W,LEE C.Diabetic macular edema:evidence-based management［J］.Indian J Ophthalmol,2018,66(12):1736-1750.
［9］　GURRERI A,PAZZAGLIA A.Diabetic macular edema:state of art and intraocular pharmacological approaches［J］.Adv Exp Med Biol,2021,1307:375-389.
［10］　ROMERO-AROCA P,BAGET-BERNALDIZ M,PAREJA-RIOS A,LOPEZ-GALVEZ M,NAVARRO-GIL R,VERGES R.Diabe-tic macular edema pathophysiology:vasogenic versus inflammatory［J］.J Diabetes Res,2016,2016:2156273.
［11］　NICOL M,FERRO DESIDERI L,VAGGE A,TRAVERSO C E.Faricimab:an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases［J］.Expert Opin Investig Drugs,2021,30(3):193-200.
［12］　KIM E J,LIN W V,RODRIGUEZ S M,CHEN A,LOYA A,WENG C Y.Treatment of diabetic macular edema［J］.Curr Diab Rep,2019,19(9):68.
［13］　MIRSHAHI R,FALAVARJANI K G,MOLAEI S,HABIBI A,ANVARI P,KHORASANI M A,et al.Macular microvascular changes after intravitreal bevacizumab injection in diabetic macular edema［J］.Can J Ophthalmol,2021,56(1):57-65.
［14］　CHEONG K X,LEE S Y,ANG M,TEO K Y C.Vessel density changes on optical coherence tomography angiography after vascular endothelial growth factor inhibitor treatment for diabetic macular edema［J］.Turk J Ophthalmol,2020,50(6):343-350.
［15］　DI G,WEIHONG Y,XIAO Z,ZHIKUN Y,XUAN Z,YI Q,et al.A morphological study of the foveal avascular zone in patients with diabetes mellitus using optical coherence tomography angiography［J］.Graefes Arch Clin Exp Ophthalmol,2016,254(5):873-879.
［16］　CAMPOCHIARO P A,WYKOFF C C,SHAPIRO H,RUBIO R G,EHRLICH J S.Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema［J］.Ophthalmology,2014,121(9):1783-1789.
［17］　ATTAALLAH H R,MOHAMED A A M,ALI M A.Macular vessels density in diabetic retinopathy:quantitative assessment using optical coherence tomography angiography［J］.Int Ophthalmol,2019,39(8):1845-1859.
［18］　SUCIU C I,SUCIU V I,NICOARA S D.Optical coherence tomography (angiography) biomarkers in the assessment and monitoring of diabetic macular edema［J］.J Diabetes Res,2020,2020:6655021.
［19］　ZHU Z,LIANG Y,YAN B,MENG Z,LONG K,ZHANG Y,et al.Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography［J］.BMC Ophthalmol,2020,20(1):382.
［20］　LEE J,MOON B G,CHO A R,YOON Y H.Optical coherence tomography angiography of DME and its association with anti-VEGF treatment response［J］.Ophthalmology,2016,123(11):2368-2375.
［21］　YU S,PANG C E,GONG Y,FREUND K B,YANNUZZI L A,RAHIMY E,et al.The spectrum of superficial and deep capillary ischemia in retinal artery occlusion［J］.Am J Ophthalmol,2015,159(1):53-63.
［22］　SPAIDE R F.Retinal vascular cystoid macular edema:review and new theory［J］.Retina,2016,36(10):1823-1842.
［23］　MOON B G,UM T,LEE J,YOON Y H.Correlation between deep capillary plexus perfusion and long-term photoreceptor recovery after diabetic macular edema treatment［J］.Ophthalmol Retina,2018,2(3):235-243.
［24］　USUI Y,WESTENSKOW P D,KURIHARA T,AGUILAR E,SAKIMOTO S,PARIS L P,et al.Neurovascular crosstalk between interneurons and capillaries is required for vision［J］.J Clin Invest,2015,125(6):2335-2346.

相似文献/References:

[1]麻南 李丹 高付林 胡莲娜.玻璃体内注射贝伐单抗和贝伐单抗/曲安奈德联合用药治疗糖尿病性黄斑水肿疗效及安全性差异的荟萃分析[J].眼科新进展,2012,32(6):000.
[2]王玲,生侠,吴清静,等.红外线及自发荧光影像在糖尿病性黄斑水肿诊断中的价值[J].眼科新进展,2014,34(8):754.[doi:10.13389/j.cnki.rao.2014.0207]
　WANG Ling,SHENG Xia,WU Qing-Jing,et al.Value of infrared ray and auto fluorescence in diagnosis of diabetic macular edema[J].Recent Advances in Ophthalmology,2014,34(4):754.[doi:10.13389/j.cnki.rao.2014.0207]
[3]杨宇,田敏,吕红彬. 糖尿病视网膜病变的治疗进展[J].眼科新进展,2015,35(5):497.[doi:10.13389/j.cnki.rao.2015.0136]
　YANG Yu,TIAN Min,LV Hong-Bin. Recent advances in treatment of diabetic retinopathy[J].Recent Advances in Ophthalmology,2015,35(4):497.[doi:10.13389/j.cnki.rao.2015.0136]
[4]李素华,高永峰. 比较单独黄斑局灶/格栅样光凝术和联合雷珠单抗治疗糖尿病性黄斑水肿的疗效[J].眼科新进展,2015,35(6):566.[doi:10.13389/j.cnki.rao.2015.0153]
　LI Su-Hua,GAO Yong-Feng. Efficacy of macular focal / grid photocoagulation combined with ranibizumab for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(4):566.[doi:10.13389/j.cnki.rao.2015.0153]
[5]夏风杰,闫峰,陆燕,等.糖尿病性黄斑水肿临床治疗进展[J].眼科新进展,2015,35(10):985.[doi:10.13389/j.cnki.rao.2015.0270]
　XIA Feng-Jie,YAN Feng,LU Yan,et al.Clinical treatment advances in diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(4):985.[doi:10.13389/j.cnki.rao.2015.0270]
[6]李秀云,朱艳,邓爱军.Ranibizumab治疗糖尿病性黄斑水肿短期疗效观察[J].眼科新进展,2016,36(1):067.[doi:10.13389/j.cnki.rao.2016.0019]
　LI Xiu-Yun,ZHU Yan,DENG Ai-Jun.Short-term efficacy of Ranibizumab for diabetic macular edema[J].Recent Advances in Ophthalmology,2016,36(4):067.[doi:10.13389/j.cnki.rao.2016.0019]
[7]陈素芳,李亨辉,邵毅,等.非诺贝特在糖尿病性黄斑水肿中的临床研究[J].眼科新进展,2016,36(2):136.[doi:10.13389/j.cnki.rao.2016.0037]
　CHEN Su-Fang,LI Heng-Hui,SHAO Yi,et al.Clinical study of fenofibrate in diabetic macular edema[J].Recent Advances in Ophthalmology,2016,36(4):136.[doi:10.13389/j.cnki.rao.2016.0037]
[8]孙光丽,姜静,王成虎,等.高密度微脉冲激光联合玻璃体内注射雷珠单抗治疗糖尿病性黄斑水肿[J].眼科新进展,2017,37(3):279.[doi:10.13389/j.cnki.rao.2017.0070]
　SUN Guang-Li,JIANG Jing,WANG Cheng-Hu,et al.High-density micropulse photocoagulation combined with intravitreal injection of ranibizumab for diabetic macular edema[J].Recent Advances in Ophthalmology,2017,37(4):279.[doi:10.13389/j.cnki.rao.2017.0070]
[9]秦艳,游志鹏,胡娇莉,等.糖尿病性黄斑水肿的药物治疗进展[J].眼科新进展,2018,38(3):281.[doi:10.13389/j.cnki.rao.2018.0066]
　QIN Yan,YOU Zhi-Peng,HU Jiao-Li,et al.Progresses in the agent treatment for diabetic macular edema[J].Recent Advances in Ophthalmology,2018,38(4):281.[doi:10.13389/j.cnki.rao.2018.0066]
[10]宋志刚,魏少华.577 nm激光光凝联合玻璃体内注射康柏西普治疗糖尿病性黄斑水肿的效果观察[J].眼科新进展,2019,39(4):373.[doi:10.13389/j.cnki.rao.2019.0085]
　SONG Zhi-Gang,WEI Shao-Hua.Effect of 577 nm laser photocoagulation combined with intravitreal injection of conbercept on diabetic macular edema[J].Recent Advances in Ophthalmology,2019,39(4):373.[doi:10.13389/j.cnki.rao.2019.0085]

备注/Memo

备注/Memo:
山东省医药卫生科技发展计划项目（编号：2019WS60）；潍坊医学院附属医院博士启动基金（编号：2020BSQD05）
更新日期/Last Update: 2022-04-05